Johnson and Johnson (J&J) announced on Wednesday that its total sales in the second quarter of fiscal 2025 stood at $23.7 billion, rising by 5.8% compared to the same period in the previous year. The figure came in above analysts' expectations.
The pharmaceutical company's diluted earnings per share (EPS) jumped by 18.7% year-on-year to reach $2.29 in the reported quarter, while its net earnings stood at $5.5 billion, surging by 18.2% from the same quarter in 2024. The company raised its estimation for full year 2025 reported sales from between $91 billion and $91.8 billion to between $93.2 billion and $93.6 billion.
"Today's strong results reflect the depth and strength of Johnson & Johnson's uniquely diversified business operating across both MedTech and Innovative Medicine," CEO Joaquin Duato said.
J&J's stock climbed by 1.31% during premarket hours after the report's release to sell for $157.21 apiece at 6:31 am ET.
